BEECH: a dose-finding run-in followed by a randomised phase II study assessing the efficacy of AKT inhibitor capivasertib (AZD5363) combined with paclitaxel in patients with estrogen receptor-positive advanced or metastatic breast cancer, and in a PIK3CA mutant sub-population.
Turner, N C
BEECH: a dose-finding run-in followed by a randomised phase II study assessing the efficacy of AKT inhibitor capivasertib (AZD5363) combined with paclitaxel in patients with estrogen receptor-positive advanced or metastatic breast cancer, and in a PIK3CA mutant sub-population. [electronic resource] - Annals of oncology : official journal of the European Society for Medical Oncology 05 2019 - 774-780 p. digital
Publication Type: Clinical Trial, Phase I; Clinical Trial, Phase II; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
1569-8041
10.1093/annonc/mdz086 doi
Antineoplastic Combined Chemotherapy Protocols--adverse effects
Biomarkers, Tumor--genetics
Breast Neoplasms--drug therapy
Class I Phosphatidylinositol 3-Kinases--genetics
Double-Blind Method
Female
Humans
Mutation
Neoplasm Metastasis
Neoplasm Recurrence, Local--drug therapy
Paclitaxel--administration & dosage
Proto-Oncogene Proteins c-akt--antagonists & inhibitors
Pyrimidines--administration & dosage
Pyrroles--administration & dosage
Receptors, Estrogen--metabolism
Survival Rate
BEECH: a dose-finding run-in followed by a randomised phase II study assessing the efficacy of AKT inhibitor capivasertib (AZD5363) combined with paclitaxel in patients with estrogen receptor-positive advanced or metastatic breast cancer, and in a PIK3CA mutant sub-population. [electronic resource] - Annals of oncology : official journal of the European Society for Medical Oncology 05 2019 - 774-780 p. digital
Publication Type: Clinical Trial, Phase I; Clinical Trial, Phase II; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
1569-8041
10.1093/annonc/mdz086 doi
Antineoplastic Combined Chemotherapy Protocols--adverse effects
Biomarkers, Tumor--genetics
Breast Neoplasms--drug therapy
Class I Phosphatidylinositol 3-Kinases--genetics
Double-Blind Method
Female
Humans
Mutation
Neoplasm Metastasis
Neoplasm Recurrence, Local--drug therapy
Paclitaxel--administration & dosage
Proto-Oncogene Proteins c-akt--antagonists & inhibitors
Pyrimidines--administration & dosage
Pyrroles--administration & dosage
Receptors, Estrogen--metabolism
Survival Rate